Alert detail

FDA Approval: SKYRIZI (RISANKIZUMAB-RZAA) — Type 3 - New Dosage Form

Policy ID: FDA-BLA761262Specialty: DermatologyAdded: 6/18/2026Effective: 2022-06-16billing update
High

Full alert analysis requires a subscription

Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.